Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
Chronic hyponatremia and skeletal vulnerability: bone loss, fragility fracture risk, and therapeutic uncertainties.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Corrêa Lucas Maciel de Almeida, Brandão Luiggi Kevin Virgino, Santiago Clara Belo Gamon, Barbosa Alexandre de Assis, Mazur Gabriel Rian, de Santana Gabriel Costa, Delmiro Silva Yan Roberth, Dante Letícia Esteves, Dutra Júnior Ivan Felipe
Аннотация
CLINICAL RELEVANCE: Chronic hyponatremia is increasingly associated with skeletal vulnerability, including lower bone mineral density (BMD), greater fragility-fracture risk, and a broader phenotype of falls and frailty. Because hyponatremia is common in older and multimorbid adults, clinicians need a practical framework for interpreting its significance in osteoporosis care.
OBSERVATIONS: Observational cohorts and meta-analyses consistently link chronic hyponatremia to lower BMD and higher fracture risk, while cellular, animal, biomarker, and selected clinical observations support biologic plausibility for a direct sodium-sensitive skeletal effect. Experimental data suggest that low extracellular sodium may stimulate osteoclastogenesis, impair osteoblast-lineage activity, alter mesenchymal stromal-cell fate, and interact with AVP-related signaling. Human evidence includes population studies, short-term remodeling-marker responses after sodium normalization, and rare clinical cases in which correction of chronic SIAD was followed by BMD recovery. However, residual confounding remains substantial, and available human data do not yet establish fracture protection, durable BMD gain, or uniform skeletal benefit across SIAD, hypervolemic hyponatremia, diuretic-associated hyponatremia, chronic kidney disease, malnutrition, or antiepileptic-drug exposure.
CONCLUSIONS: Chronic hyponatremia should be regarded as a phenotype-sensitive skeletal risk signal and biologically plausible contributor to bone vulnerability, with the strongest causal arguments arising from chronic SIAD and experimental models, but it should not yet be treated as an evidence-based osteoporosis-treatment target in the absence of fracture or durable BMD endpoint data. In current practice, it should prompt fracture-risk contextualization, evaluation of falls, nutrition, muscle reserve, and secondary contributors to bone loss, while expectations regarding skeletal benefit from sodium correction remain cautious and evidence-based.
OBSERVATIONS: Observational cohorts and meta-analyses consistently link chronic hyponatremia to lower BMD and higher fracture risk, while cellular, animal, biomarker, and selected clinical observations support biologic plausibility for a direct sodium-sensitive skeletal effect. Experimental data suggest that low extracellular sodium may stimulate osteoclastogenesis, impair osteoblast-lineage activity, alter mesenchymal stromal-cell fate, and interact with AVP-related signaling. Human evidence includes population studies, short-term remodeling-marker responses after sodium normalization, and rare clinical cases in which correction of chronic SIAD was followed by BMD recovery. However, residual confounding remains substantial, and available human data do not yet establish fracture protection, durable BMD gain, or uniform skeletal benefit across SIAD, hypervolemic hyponatremia, diuretic-associated hyponatremia, chronic kidney disease, malnutrition, or antiepileptic-drug exposure.
CONCLUSIONS: Chronic hyponatremia should be regarded as a phenotype-sensitive skeletal risk signal and biologically plausible contributor to bone vulnerability, with the strongest causal arguments arising from chronic SIAD and experimental models, but it should not yet be treated as an evidence-based osteoporosis-treatment target in the absence of fracture or durable BMD endpoint data. In current practice, it should prompt fracture-risk contextualization, evaluation of falls, nutrition, muscle reserve, and secondary contributors to bone loss, while expectations regarding skeletal benefit from sodium correction remain cautious and evidence-based.